Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
23847studies shown
Showing 23,821-23,832 of 23,847
Drug study icon
UnknownNCT06481787

Zuojin Wan Combined With Woonosan Fumarate for GRD Combined With Depression

This study is looking at whether Vonorasan Fumarate can help people with Gastroesophageal Reflux Disease or Depression. Participants receive a study treatment and complete follow-up visits and assessments.

Location not clearly listed
DepressionDrugFrom 18 Years to 65 Years
Countries
Sponsor
Nanjing First Hospital, Nanjing Medical University
Condition
Depression
Other study type icon
CompletedNCT02401984

Zurcher Adolescent Screening for Mental Disorder

This summary needs review. Please check the official study record and contact the research team for details.

In Zurich
Mental healthOtherFrom 16 Years to 25 Years
Countries
Switzerland
Sponsor
Filomena Sabatella
Condition
Mental health
Drug study icon
WithdrawnNCT00440843

Zyprexa and Task Engagement in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In New York
SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
VA Connecticut Healthcare System
Condition
Schizophrenia
Other study type icon
Enrolling By InvitationNCT01088386

Zyprexa® Relprevv™ Patient Care Program

This observational study is following people with Schizophrenia to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.

In Blue Bell
SchizophreniaOtherOver 18 Years
Countries
United States
Sponsor
Eli Lilly and Company
Condition
Schizophrenia
Drug study icon
CompletedNCT07434401

α-N-acetylgalactosaminidase in Methamphetamine Psychosis

This study exists to learn from real-world information that can show how smoking support or smoking-related treatment fits into care. Researchers are trying to understand whether smoking support or smoking-related treatment can work better when mental health difficulties overlap with substance use.

In Elâzığ
SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Türkiye
Sponsor
Elazığ Mental Health and Diseases Hospital
Condition
Schizophrenia
Other study type icon
CompletedNCT07673718

α-N-acetylgalactosaminidase in Schizoaffective Disorder

This summary needs review. Please check the official study record and contact the research team for details.

In Elâzığ
SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Türkiye
Sponsor
Elazığ Mental Health and Diseases Hospital
Condition
Schizophrenia
Biological study icon
CompletedNCT07424911

α-N-acetylgalactosaminidase Levels in Panic Disorder

This study exists to understand how blood tests and biological markers holds up over time after the earliest research stage. Researchers are trying to understand what blood tests and biological markers can reveal about signals in the brain or body that may guide care later on.

In Elâzığ
AnxietyOtherFrom 18 Years to 65 Years
Countries
Türkiye
Sponsor
Elazığ Mental Health and Diseases Hospital
Condition
Anxiety
Behavioral study icon
CompletedNCT04362982

Αn Information System for Symptom Diagnosis and Improvement of Attention Deficit Hyperactivity Disorder (ADHD360)

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

In Thessaloniki
ADHDBehavioralFrom 7 Years to 16 Years
Countries
Greece
Sponsor
Aristotle University Of Thessaloniki
Condition
ADHD
Drug study icon
Active Not RecruitingNCT07047651

Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.

This study is looking at whether Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram), can help people with Treatment Resistant Schizophrenia or Treatment Resistant bipolarity. Participants take part in Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram), and complete follow-up assessments.

In Athens
Schizophrenia, BipolarityDrugFrom 18 Years to 65 Years
Countries
Greece
Sponsor
Dr. Stavroula Rakitzi
Condition
Schizophrenia, Bipolarity
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.